H J Lück
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
Möbus V, Kurbacher C, Untch M, Konecny G, Hinke A, Runnebaum I, von Minckwitz G, Harbeck N, Huober J, Schneeweiss A, Nitz U, Kuhn W, Thomssen C, du Bois A, Lück H, Jackisch C, AGO Breast Study Group (AGO-B). Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol 2018; 29:178-185.
Jan 1, 2018Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
Jan 1, 2018Ann Oncol 2018; 29:178-185
Möbus V, Kurbacher C, Untch M, Konecny G E, Hinke A, Runnebaum I B, von Minckwitz G, Harbeck N, Huober Jens, Schneeweiss A, Nitz U, Kuhn W, Thomssen C, du Bois A, Lück H J, Jackisch C, AGO Breast Study Group (AGO-B)
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
Baumann K, Lück H, Vergote I, Schmalfeldt B, Huober J, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 2011; 123:27-32.
Jul 5, 2011Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
Jul 5, 2011Gynecol Oncol 2011; 123:27-32
Baumann K, Lück H J, Vergote I, Schmalfeldt B, Huober Jens, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U